BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35023616)

  • 1. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
    Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
    Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR co-mutation is associated with the risk of recurrence in invasive lung adenocarcinoma with the micropapillary component.
    Kang H; Lv H; Tung TH; Ma D; Wang Z; Du J; Zhou K; Pan J; Zhang Y; Peng S; Yu Z; Shen B; Ye M
    Asian J Surg; 2024 Jan; 47(1):201-207. PubMed ID: 37574361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
    Lee JS; Kim EK; Kim KA; Shim HS
    Cancer Res Treat; 2024 Jan; 56(1):104-114. PubMed ID: 37499696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
    Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
    Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
    Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
    Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.
    Aoki M; Miyata R; Kamimura G; Harada Takeda A; Suetsugu T; Mizuno K; Ueda K
    Ann Thorac Cardiovasc Surg; 2024 Jan; 30(1):. PubMed ID: 38105006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
    BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, Genomic, and Transcriptomic Featurses of Lung Adenocarcinoma With Uncommon EGFR Mutation.
    Hayasaka K; Takeda H; Sakurada A; Matsumura Y; Abe J; Shiono S; Notsuda H; Suzuki H; Endo M; Motohashi H; Okada Y
    Clin Lung Cancer; 2024 Jan; 25(1):e43-e51. PubMed ID: 37985312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
    BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
    Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
    Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
    Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
    Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.
    Liu X; Li X; Zhang C; Jin J; Wang Z; Xiao R; Sun K; Wang J; Zhong W; Yang F
    Lung Cancer; 2022 May; 167():78-86. PubMed ID: 35427848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
    Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
    BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation Profile of Resected
    Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
    Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
    Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
    Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
    PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.